Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1964 2
1965 1
2011 1
2014 1
2020 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for E. pokroky
Your search for E. Rokrok retrieved no results
[Gastrointestinal stromal tumor (GIST): advances in 2013].
Daum O, Sedivcová M. Daum O, et al. Cesk Patol. 2014 Apr;50(2):76-80. Cesk Patol. 2014. PMID: 24758502 Czech.
Pharmacogenomics have been successful in designing drugs to overcome not only the primary resistance of GISTs to the action of imatinib (e.g. GISTs with a substitution of Asp842Val in exon 18 PDGFRA or SDHB-deficient GISTs), but also the secondary resistance caused by seco …
Pharmacogenomics have been successful in designing drugs to overcome not only the primary resistance of GISTs to the action of imatinib ( …
[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Heneberg P. Heneberg P. Klin Onkol. 2011;24(4):256-64. Klin Onkol. 2011. PMID: 21905615 Review. Czech.
Apart from administration of imatinib for a small subgroup of melanomas harbouring KIT mutations, the most promising approach is the use of B-RAF kinase inhibitors. The previously tested RAF inhibitors (e.g. sorafenib) did not perform better compared to conventional chemot …
Apart from administration of imatinib for a small subgroup of melanomas harbouring KIT mutations, the most promising approach is the use of …